Perspective Therapeutics (NYSE:CATX) Price Target Cut to $16.00 by Analysts at Oppenheimer

Perspective Therapeutics (NYSE:CATX) had its target price reduced by Oppenheimer from $22.00 to $16.00 in a report published on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts also recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. UBS Group initiated coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Truist Financial started coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Royal Bank of Canada cut their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Price Performance

CATX stock opened at $3.69 on Friday. The company’s 50-day moving average is $11.33. Perspective Therapeutics has a 52-week low of $2.28 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, analysts forecast that Perspective Therapeutics will post -0.86 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $57,000. US Bancorp DE grew its position in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics during the 2nd quarter worth $117,000. Point72 DIFC Ltd acquired a new stake in shares of Perspective Therapeutics in the 2nd quarter worth $118,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Perspective Therapeutics in the third quarter valued at about $137,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.